STAAR Surgical Swings to Loss Amid Alcon Merger Costs, Sales Dip

TL;DR

**STAAR Surgical is bleeding cash and sales, making Alcon's $28/share offer a necessary, albeit potentially undervalued, lifeline.**

AI Summary

STAAR Surgical Co. reported a net loss of $62.139 million for the nine months ended September 26, 2025, a significant decline from a net income of $14.020 million in the same period of 2024. This was primarily driven by a substantial increase in 'Restructuring, impairment and related charges' to $27.938 million and 'Merger transaction and related costs' of $5.926 million, both absent in the prior year. Net sales for the nine-month period decreased to $181.641 million from $264.951 million, a 31.4% reduction. However, for the three months ended September 26, 2025, net sales increased to $94.732 million from $88.590 million in the prior year, and net income was $8.884 million, down from $9.980 million. The company is undergoing a proposed merger with Alcon, with stockholders set to vote on December 3, 2025, for a cash consideration of $28.00 per share. Cash and cash equivalents increased to $176.155 million from $144.159 million at December 27, 2024.

Why It Matters

This filing reveals STAAR Surgical's significant financial challenges, including a substantial net loss and declining nine-month sales, even as it navigates a proposed acquisition by Alcon. For investors, the $28.00 per share cash offer from Alcon provides a clear exit, but the Broadwood Group's opposition suggests potential for a higher valuation or a contested merger. Employees face uncertainty due to leadership realignments and workforce reductions, while customers might see product development shifts under new ownership. The competitive landscape in implantable lenses could be reshaped if Alcon integrates STAAR's technology, potentially impacting market dynamics and innovation.

Risk Assessment

Risk Level: high — The company reported a net loss of $62.139 million for the nine months ended September 26, 2025, a stark contrast to a $14.020 million net income in the prior year. This loss is exacerbated by $27.938 million in restructuring and impairment charges and $5.926 million in merger transaction costs, indicating significant operational and strategic upheaval. Furthermore, net sales for the nine-month period dropped by 31.4% to $181.641 million from $264.951 million, signaling substantial business contraction.

Analyst Insight

Investors should closely monitor the December 3, 2025, stockholder vote on the Alcon merger, especially given Broadwood Group's opposition. Consider the $28.00 cash offer as a floor, but be aware of potential volatility if the merger faces further delays or a competing bid emerges. Given the significant net loss and sales decline, a quick exit via the merger might be prudent for risk-averse investors.

Financial Highlights

revenue

$181.641M

net Income

-$62.139M

cash Position

$176.155M

revenue Growth

-31.4%

Revenue Breakdown

Key Numbers

• $62.139M — Net Loss (For nine months ended Sept 26, 2025, compared to $14.020M net income in prior year.)
• $181.641M — Net Sales (For nine months ended Sept 26, 2025, down 31.4% from $264.951M in prior year.)
• $27.938M — Restructuring & Impairment Charges (For nine months ended Sept 26, 2025, significantly impacting profitability.)
• $5.926M — Merger Transaction Costs (For nine months ended Sept 26, 2025, related to the proposed Alcon merger.)
• $28.00 — Per Share Merger Price (Cash offer from Alcon for each STAAR Surgical common stock share.)
• $176.155M — Cash and Cash Equivalents (As of September 26, 2025, an increase from $144.159M at December 27, 2024.)
• $43.4M — Company Termination Fee (Potential fee STAAR Surgical may pay Alcon if merger agreement is terminated under specified circumstances.)
• $72.4M — Alcon Termination Fee (Potential fee Alcon may pay STAAR Surgical if merger agreement is terminated under certain circumstances.)
• 49,741,953 — Common Shares Outstanding (As of October 31, 2025.)
• 31.4% — Nine-Month Sales Decrease (Percentage decrease in net sales from $264.951M to $181.641M year-over-year.)

Key Players & Entities

• STAAR Surgical Co. (company) — Registrant and target of proposed merger
• Alcon Research, LLC (company) — Acquirer in proposed merger
• Rascasse Merger Sub, Inc. (company) — Wholly owned subsidiary of Alcon, merging with STAAR Surgical
• Broadwood Partners, L.P. (company) — Shareholder group opposing the proposed merger
• $62.139 million (dollar_amount) — Net loss for the nine months ended September 26, 2025
• $181.641 million (dollar_amount) — Net sales for the nine months ended September 26, 2025
• $28.00 (dollar_amount) — Cash per share offer in the proposed merger with Alcon
• $27.938 million (dollar_amount) — Restructuring, impairment and related charges for the nine months ended September 26, 2025
• $5.926 million (dollar_amount) — Merger transaction and related costs for the nine months ended September 26, 2025
• December 3, 2025 (date) — Postponed date for the Special Meeting of stockholders to vote on the Merger Agreement

FAQ

Risk Factors

• Significant Net Loss and Revenue Decline [high — financial]: The company reported a net loss of $62.139 million for the nine months ended September 26, 2025, a stark contrast to a net income of $14.020 million in the prior year. This was accompanied by a 31.4% decrease in net sales to $181.641 million.
• Restructuring and Impairment Charges [high — operational]: A substantial increase in 'Restructuring, impairment and related charges' to $27.938 million for the nine-month period significantly impacted profitability. These charges were absent in the prior year.
• Merger Transaction Risks [high — legal]: The proposed merger with Alcon involves 'Merger transaction and related costs' of $5.926 million for the nine-month period. Potential termination fees, such as the $43.4 million payable by STAAR Surgical or $72.4 million payable by Alcon, represent significant financial risks.
• Dependence on Merger Outcome [high — market]: The company's future is heavily dependent on the successful completion of the proposed merger with Alcon, with a stockholder vote scheduled for December 3, 2025. Any failure to complete the merger could have adverse effects.
• Regulatory Approvals for Merger [medium — regulatory]: The merger is subject to customary closing conditions, including regulatory approvals. Delays or failure to obtain these approvals could jeopardize the transaction.

Industry Context

The ophthalmic surgical device market, particularly for refractive procedures like those involving STAAR Surgical's lenses, is competitive and driven by technological innovation and patient demand for vision correction. Companies in this space often face rigorous regulatory scrutiny and require substantial R&D investment. The proposed merger with Alcon, a major player in the eye care industry, suggests a trend towards consolidation or strategic partnerships to gain market share and leverage scale.

Regulatory Implications

The proposed merger with Alcon will require approval from various regulatory bodies, including antitrust authorities in relevant jurisdictions. Delays or conditions imposed by these regulators could impact the transaction's timeline and ultimate success. Furthermore, STAAR Surgical's products are subject to medical device regulations in all markets where they are sold, requiring ongoing compliance.

What Investors Should Do

1. Monitor Merger Vote Outcome
2. Assess Standalone Viability Post-Merger Decision
3. Evaluate Cash Position and Burn Rate

Key Dates

• 2025-09-26: Nine months ended September 26, 2025 — Period marked by significant net loss, increased restructuring charges, and decreased net sales compared to the prior year.
• 2025-12-03: Stockholder vote on Alcon merger — Crucial date for determining the future of STAAR Surgical, with a proposed cash consideration of $28.00 per share.
• 2024-12-27: Cash and cash equivalents balance — Reported cash and cash equivalents of $144.159 million at this date, providing a baseline for comparison.

Glossary

Restructuring, impairment and related charges

Costs incurred due to significant organizational changes, asset write-downs, or other one-time events aimed at improving future efficiency or reflecting diminished asset value. (These charges of $27.938 million significantly impacted the company's net loss for the nine-month period.)

Merger transaction and related costs

Expenses associated with the process of acquiring or merging with another company, including legal, accounting, and advisory fees. (These costs amounted to $5.926 million for the nine-month period, directly related to the proposed Alcon merger.)

Cash consideration

The amount of cash paid to shareholders in exchange for their shares in a merger or acquisition. (Alcon is offering $28.00 per share in cash for STAAR Surgical's common stock.)

Termination Fee

A penalty paid by one party to another if a contract, such as a merger agreement, is terminated under specific circumstances. (Both STAAR Surgical ($43.4M) and Alcon ($72.4M) could be liable for termination fees, representing significant financial implications.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, STAAR Surgical has experienced a dramatic shift from profitability to a substantial net loss of $62.139 million, driven by $27.938 million in restructuring and impairment charges and $5.926 million in merger costs. Net sales have declined by 31.4% to $181.641 million. While the most recent quarter (Q3 2025) showed a modest revenue increase of 7.0%, the overall trend for the year-to-date period is negative, exacerbated by significant one-time charges.

Key Financial Figures

• $0.01 — 1,953 shares of common stock, par value $0.01 per share, issued and outstanding as of
• $5,926,000 — curred professional service expenses of $5,926,000 during the three months ended September

Filing Documents

• staa-20250926.htm (10-Q) — 3069KB
• staa-ex31_1.htm (EX-31.1) — 16KB
• staa-ex31_2.htm (EX-31.2) — 16KB
• staa-ex32_1.htm (EX-32.1) — 18KB
• 0001193125-25-266879.txt ( ) — 12445KB
• staa-20250926.xsd (EX-101.SCH) — 1301KB
• staa-20250926_htm.xml (XML) — 2818KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION 1 ITEM 1

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 1 ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 22 ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 29 ITEM 4.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 29

– OTHER INFORMATION

PART II – OTHER INFORMATION 30 ITEM 1.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 30 ITEM 1A.

RISK FACTORS

RISK FACTORS 30 ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 32 ITEM 4. MINE SAFETY DISCLOSURES 32 ITEM 5. OTHER INFORMATION 32 ITEM 6. EXHIBITS 33

– FINANCI AL INFORMATION

PART I – FINANCI AL INFORMATION

FINANCI AL STATEMENTS

ITEM 1. FINANCI AL STATEMENTS STAAR SURGICAL COMPANY CONDENSED CONSOLIDA TED BALANCE SHEETS (In thousands, except par value amounts) (Unaudited) September 26, 2025 December 27, 2024 ASSETS Current assets: Cash and cash equivalents $ 176,155 $ 144,159 Investments available for sale (amortized cost basis of $ 16,504 and $ 86,346 at September 26, 2025 and December 27, 2024, respectively) 16,505 86,335 Accounts receivable trade, net of allowance for credit losses of $ 83 and $ 32 at September 26, 2025 and December 27, 2024, respectively 60,105 77,897 Inventories, net 53,302 43,305 Prepayments, deposits and other current assets 15,142 16,244 Total current assets 321,209 367,940 Property, plant and equipment, net 72,605 84,889 Finance lease right-of-use assets, net — 37 Operating lease right-of-use assets, net 31,339 36,850 Goodwill 1,786 1,786 Deferred income taxes 1,977 788 Other assets 27,446 17,234 Total assets $ 456,362 $ 509,524 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 9,180 $ 16,704 Obligations under finance leases — 42 Obligations under operating leases 5,314 3,894 Allowance for sales returns 7,526 6,579 Other current liabilities 39,617 43,087 Total current liabilities 61,637 70,306 Obligations under operating leases 33,803 34,807 Deferred income taxes — 297 Asset retirement obligations 43 42 Deferred rent 89 — Pension liability 7,010 6,737 Total liabilities 102,582 112,189 Commitments and contingencies Stockholders' equity: Common stock, $ 0.01 par value; 60,000 shares authorized: 49,730 and 49,294 shares issued and outstanding at September 26, 2025 and December 27, 2024, respectively 497 493 Additional paid-in capital 495,986 471,449 Treasury stock, 376 and 0 shares at September 26, 2025 and December 27, 2024, respectively ( 6,4

View Full Filing

View this 10-Q filing on SEC EDGAR